Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype

Abstract EN

Prenatally administered rosiglitazone (RGZ) is effective in enhancing lung maturity; however, its long-term safety remains unknown.

This study aimed to determine the effects of prenatally administered RGZ on the metabolic phenotype of adult rats.

Methods.

Pregnant Sprague-Dawley rat dams were administered either placebo or RGZ at embryonic days 18 and 19.

Between 12 and 20 weeks of age, the rats underwent glucose and insulin tolerance tests and de novo fatty acid synthesis assays.

The lungs, liver, skeletal muscle, and fat tissue were processed by Western hybridization for peroxisome proliferator-activated receptor (PPAR)γ, adipose differentiation-related protein (ADRP), and surfactant proteins B (SPB) and C (SPC).

Plasma was assayed for triglycerides, cholesterol, insulin, glucagon, and troponin-I levels.

Lungs were also morphometrically analyzed.

Results.

Insulin and glucose challenges, de novo fatty acid synthesis, and all serum assays revealed no differences among all groups.

Western hybridization for PPARγ, ADRP, SPB, and SPC in lung, liver, muscle, and fat tissue showed equal levels.

Histologic analyses showed a similar number of alveoli and septal thickness in all experimental groups.

Conclusions.

When administered prenatally, RGZ does not affect long-term fetal programming and may be safe for enhancing fetal lung maturation.